Barginear M, et al. - Given that a direct association between older age and chemotherapy-induced neuropathy has been reported in a few previous studies, researchers investigated age-based differences in chemotherapy-induced neuropathy in this present study which is based on CALGB 40101 which investigated adjuvant paclitaxel (80 mg/m² once per week or 175 mg/m² every 2 weeks) in patients with breast cancer. They used Common Terminology Criteria for Adverse Events version 4 to assess grade 2 or worse neuropathy (primary endpoint) in patients at baseline, every 6 months for 2 years, and then annually for 15 years. Findings demonstrated that the occurrence of paclitaxel-induced neuropathy was common but older age was not an independent risk factor.